SequelSEC

SCYNEXIS INC SCYX

Pharmaceutical Preparations · CIK 0001178253 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$235.00K
Fiscal year ended 2026-06-30
Operating income
-$7.78M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$25.65MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.57Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth449.9%92th
Current ratio7.04x71th
Operating margin-78.0%63th
Net margin-41.8%61th
SBC / revenue13.8%41th
R&D / revenue108.2%44th

SCYNEXIS INC (SCYX) reported revenue of $235.00K and net income of $7.40M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SCYNEXIS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SCYNEXIS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$235.00K$0$18.65M$334.00K$1.36M$257.00K$977.00K$660.00K$736.00K$1.37M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$7.78M-$16.94M$10.52M-$8.40M-$9.56M-$8.61M-$8.05M-$10.32M-$9.24M-$9.51M
Net income$7.40M-$21.30M$12.26M-$8.59M-$6.88M-$5.39M-$4.43M-$2.81M-$14.46M$411.00K
Research & development$3.89M$12.35M$4.54M$5.45M$7.14M$5.14M$4.31M$8.07M$6.81M$7.21M
Weighted-average diluted sharesshares 11.82Mshares 50.96MUnavailableshares 49.90Mshares 6.22Mshares 49.44MUnavailableshares 48.62Mshares 48.51Mshares 48.57M
Pretax incomeUnavailableUnavailable$12.26M-$8.59M-$6.88M-$5.39M-$4.41M-$3.20M-$14.46M$942.00K
Income tax expenseUnavailableUnavailable$0$0$0$0$23.00K-$395.00K$0$531.00K
Diluted EPS$0.63$-0.42Unavailable$-0.17$-1.11$-0.11Unavailable$-0.06$-0.30$0.01
Selling, general & administrative$4.12M$4.59M$3.58M$3.29M$3.78M$3.73M$4.72M$2.91M$3.17M$3.67M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SCYNEXIS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$10.49M$36.67M$21.26M$14.80M$11.02M$6.94M$16.05M$28.73M$25.99M$35.48M
Total assets$74.97M$77.63M$59.03M$51.07M$60.69M$67.92M$90.64M$99.04M$107.81M$118.25M
Current assets$56.24M$62.69M$40.37M$48.69M$56.50M$52.22M$72.18M$80.46M$94.58M$101.67M
Total liabilities$8.04M$36.32M$9.65M$14.64M$16.23M$17.38M$35.57M$40.51M$47.40M$44.15M
Current liabilities$5.82M$15.90M$5.73M$8.47M$10.86M$8.96M$24.10M$25.72M$25.23M$27.35M
Total equity incl. NCI$66.93M$41.31M$49.38M$36.43M$44.47M$50.53M$55.08M$58.53M$60.41M$74.10M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.26M$5.63M$2.22M$3.47M$6.17M$4.26M$4.57M$4.96M$5.35M$8.92M

Cash flow

SCYNEXIS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$14.88M-$8.10M$18.40M-$8.72M-$7.50M-$7.46M-$9.91M$765.00K-$10.86M-$4.01M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$24.76M-$525.00K-$11.82M$12.42M$11.27M$12.44M-$2.62M$1.94M$1.37M$5.45M
Financing cash flow$13.46M$24.04M-$115.00K$29.00K$0-$14.08M-$155.00K$31.00K$0-$15.00K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$568.00K$580.00K$687.00K$526.00K$820.00K$819.00K$981.00K$901.00K$759.00K$705.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$0

Derived

SCYNEXIS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-3308.5%Unavailable56.4%-2516.5%-701.0%-3350.2%-824.3%-1563.6%-1255.0%-692.5%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue241.7%Unavailable3.7%157.5%60.1%318.7%100.4%136.5%103.1%51.3%
Current ratio9.65x3.94x7.04x5.75x5.20x5.83x3.00x3.13x3.75x3.72x
Revenue YoY growth-82.8%-100.0%1808.5%-49.4%85.3%-81.3%-83.1%-62.5%-99.4%21.5%
Net margin3147.7%Unavailable65.7%-2572.2%-504.8%-2097.7%-453.7%-425.5%-1964.4%29.9%
R&D / revenue1655.7%Unavailable24.4%1632.3%523.5%2000.4%441.6%1223.2%924.9%525.3%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable56.4%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SCYX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.